Zymeworks Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Perfect. Hi, everyone. My name is Phoebe Tan, and I work with Akash Tewari. Today, I have the pleasure of hosting Zymeworks, and I will hand it off to Ken, the CEO, for some intro remarks.
That is great. Happy to be back here again. Thanks for the invitation. 2026 has been a great year for Zymeworks so far, and there are six weeks left in the year, so we are not finished yet. It is like we have been able to show from the beginning of the year just executing the different parts of this diversified model of biotech that we believe strongly in. I think some of the transactions and things we have done this year can provide a good example of what we think we can do. For 2027 and 2028, you are just going to see more of the same, but just more of it, better, faster, higher quality as we move to build Zymeworks the way that we have laid out last year at your conference.
Perfect. I wanted to start with ZW209, your trispecific DLL3, that you just did a licensing deal with Roche. First, can you talk about what excites you about this asset and where you think it may differentiate versus the other DLL3 approaches, ADCs, and TCEs? Also, what early data could you maybe indicate that Roche might have seen that kind of got them excited as well?
Yeah, great. I think we are excited about a bunch of things about ZW209 and the Roche deal. I think first and foremost, our little 100-person R&D group in Vancouver continues to create differentiated molecules and do things that no one else has been able to do, or no one else seems to be able to copy. I think beyond zanidatamab and pasritamig, I think ZW209 is a really unique co-stim platform, building in two signals into one biologic. Roche certainly validated our approach of being different by having They had access to other trispecifics they could have- chosen inside Roche, or externally, from around the world.
But they found what they were looking for in Vancouver, and I think they were impressed by the preclinical data and the quality of it that will hopefully translate into the clinic. Really, it's just a unique, divergent approach that we've taken that no one else seems to be able to do with their platforms. That's really exciting. I think partnering with Roche before going to clinical studies was definitely a strategic choice for us, rather than taking it further ourself.
I think as we look at small cell lung cancer becoming much more competitive, also the fact that maybe combination strategies will win the day with patients. We've certainly seen people take ADC approaches, T-cell engager approaches. We're certainly taking the idea of building signal one and signal two into a single molecule, also the impact of immunotherapy or maybe two out of those three, or potentially all three of those being used in combination.
I think partnering with Roche, who already has access to the other components which could be added to ZW209, is pretty exciting.
I think we were really excited by the data that we saw at SITC last year, or last week, or two weeks ago maybe, from our partner J&J, looking at combining pasritamig, which is a CD3 T-cell engager against KLK2 prostate cancer, with a PSMA CD28. So a signal one, signal two approach in how we think about being more efficient with T-cell engagers and mobilizing more when they're exhausted, or mobilizing more initially and making them more functional approach. That was interesting, as in two different bispecific antibodies combined together. But we certainly think it validates this idea that a signal two can be beneficial, versus an initial activation of T-cells by CD3. We're hoping we can show that in a single biologic structure, with our controlled, conditionally activated CD28 approach.
Great. When should we expect initial data, and what would you want to see that you would consider exciting?
Yeah, I know you don't like the answer. We just won't give any guidance on when you'll see data. We've stuck very firmly to what we think is the right approach, which is any clinical data that's presented has to have something meaningful to say, and it's always in a peer-reviewed format.
You won't see it in a press release. You won't see it at an R&D day. You'll see it in a peer-reviewed format with the right amount of integrity behind that data, and when something meaningful has been seen. Obviously, if you look at our prior compounds we put in the clinic the last couple years, we go very fast in dose escalation, dose optimization to get that answer. Certainly, having Roche allow us to start the clinical study this year in the dose escalation is, I think, a sign that they like that momentum and speed and quality we can generate to get enough data right away to make answers, to make decisions about what to do next.
We'll bring that efficiency that we've built in our clinical trial unit to Roche, which is kind of ironic. I think we can just keep the momentum of that program going really quickly.
Okay. Understood. In general, this seems like one potential deal structure for Zymeworks in your early pipeline. Can you talk about any other potential deal structures, partnerships, or full sale? You are partnering and you are working on the phase I together. How should we look at potential future deals?
Yeah, I think it is a good question. There are two important things at Zymeworks that I think differentiate us a little bit that we pay attention to. One is, we have this financial foundation with our commercial royalties and assets, which gives us a really nice financial foundation, which every day is becoming more predictable, more durable. That is one part of it. The second part is we have a ridiculously productive and efficient R&D group, that continues to create unique and differentiated molecules that no one else is working on. Then I think when we think about that, we have to find a way to move a pretty broad and diverse portfolio forward, but just not on our own balance sheets.
We make very careful decisions about what we finance ourselves off our own balance sheet and a part of that financial foundation, and keep things unencumbered, and we will always have a segment there. We think very clearly about where a partnership might be the way to access capital and resources and speed and competitive advantage, which you can see with the Roche deal with ZW209. Then we also have this other element where we think there might be parts of our portfolio, which is pretty rich, to carve out and create a dedicated team, dedicated capital in a separate entity that we can keep an equity share in and a royalty obligation to the underlying assets and move that forward. We have certainly seen that with our pan-RAS ADC portfolio, which we worked on for two years.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
